China approves AstraZeneca’s heart failure drug Forxiga
February 4, 2021AstraZeneca, Forxiga
AstraZeneca’s Forxiga (dapagliflozin) has been approved for use in China to reduce the risk of death and hospitalisation from heart …
Raremark appoints Caroline O’Connor as CCO
February 4, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer. Previously holding the position of Raremark’s Senior Vice President …
Pfizer and Imcyse enter research and licence agreement for rheumatoid arthritis programme
February 4, 2021Imcyse, Pfizer
Imcyse has entered into a research collaboration and licence agreement with Pfizer for Imcyse’s rheumatoid arthritis (RA) programme based on …
NICE recommends MSD’s Keytruda in combination with chemotherapy for lung cancer
February 4, 2021Cancer, MSD
NICE has recommended MSD’s Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy (pembrolizumab combination) as a first-line option for untreated, metastatic, …
Jazz acquires GW Pharmaceuticals in $7.2 billion deal
February 4, 2021cannabinoid, jazz pharmaceuticals
Jazz Pharmaceuticals has acquired GW Pharmaceuticals for over $7 billion, with the transition expected to close in the second quarter …
Pharmafile.com’s weekly COVID-19 news round-up
February 3, 2021Research and Development COVID-19
The past week has seen mostly positive COVID-19 vaccine developments; Pfizer has confirmed its jab is effective against both the …
Longer Oxford-AstraZeneca vaccine interval improves efficacy, report says
February 3, 2021Research and Development AstraZeneca, COVID-19
A longer interval between doses of the Oxford University-AstraZeneca vaccine could substantially improve efficacy, according to a report published in …
GSK and CureVac sign £132m deal to develop next-generation COVID-19 vaccine
February 3, 2021Research and Development COVID-19, CureVac, GlaxoSmithKline
GlaxoSmithKline (GSK) and CureVac have today announced they are joining forces to develop a new COVID-19 vaccine to combat future …
CHMP recommends marketing authorisation for Incyte’s pemigatinib
February 3, 2021Research and Development EMA, Incyte
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Incyte’s pemigatinib for …
New urine test could detect womb cancer in three hours
February 3, 2021Research and Development Cancer, urine test
A simple test using patented technology to detect the cancer biomarker MCM5 (Minichromosome Maintenance Complex Component 5) in urine could …
Scenic Biotech appoints Dr Philippe Dro as Chairman
February 2, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Scenic Biotech has announced the appointment of Dr Philippe Dro as its independent Chairman. Dr Dro replaces Dr Ulrich Grau, …
Chelsea & Westminster Hospital launches diabetes care app
February 2, 2021Manufacturing and Production
Chelsea and Westminster Hospital NHS Foundation Trust have today announced the use of a new app designed to revolutionise diabetes …
FDA approves new IM administration route for Biogen’s MS drug Plegridy
February 2, 2021Manufacturing and Production Biogen, MS
The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …
Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds
February 2, 2021Manufacturing and Production Cancer, MSD
A new trial by Merck – known as MSD outside of North America – has found that their lung cancer …
EMA recommends Arvelle’s seizure drug cenobamate
February 2, 2021Manufacturing and Production Arvelle Therapeutics, epilepsy
The EMA has recommended the approval of Arvelle Therapeutics’ cenobamate for the adjunctive treatment of focal onset seizures with or …
Adamas’ Parkinson’s drug gets US marketing authorisation for second indication
February 2, 2021Manufacturing and Production Adamas Pharmaceuticals, FDA
The FDA has granted marketing authorisation for a second indication for Adamas Pharmaceuticals’ Gocovri (amantadine) extended release capsules. The drug …
EMA grants marketing authorisation for Amarin’s heart attack treatment
February 1, 2021Sales and Marketing Amarin, EMA
Amarin have been granted authorisation from the EMA to market a treatment that will reduce the chance of heart attacks …
Johnson & Johnson’s single-shot COVID-19 vaccine 85% effective
February 1, 2021Sales and Marketing COVID-19, Johnson & Johnson, vaccines
Johnson & Johnson has announced that its COVID-19 vaccine candidate is 85% effective in preventing serious symptoms of the disease, …
Bayer’s venous thromboembolism drug Xarelto gets UK approval for children
February 1, 2021Sales and Marketing Bayer
Bayer has received UK approval for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism …
Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels
February 1, 2021Sales and Marketing Sosei Heptares
Sosei Heptares has announced it will collaborate with Metrion Biosciences, a specialist ion channel CRO and drug discovery company, to …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
